“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
HOME > ACADEMIA
ACADEMIA
- Opdivo-Induced Myasthenia Gravis Tends to Become Severe: Keio Researchers
August 21, 2017
- Japan Gastric Cancer Association to Wait for Opdivo Nod before Guidelines Update, Keytruda Won’t Make It This Time
August 16, 2017
- NCCHD to Launch Panel to Study Real-World Drug Use in Children, Findings Might Be Used for Label Revisions
August 8, 2017
- Kyoto Univ. to Commence Trial of Drug Candidate Discovered in iPS Cells Research for Rare Bone Disease
August 3, 2017
- Drug Vial Optimization Reduces Drug Expenditure, with Biggest Savings for Opdivo: Study
August 2, 2017
- Hypertension Treatment Guidelines for Elderly Finalized with Recommendations on Dosage Reduction, Discontinuation
July 21, 2017
- JSHR to Conduct 20-Year Follow-Up Study in Up to 100,000 Patients to Determine Efficacy of H. Pylori Eradication Therapy at Preventing Stomach Cancer
July 14, 2017
- New Treatment GL for Advanced HCC to Be Issued in October, Will Recommend Nexavar for 1st-Line Treatment
July 11, 2017
- Cure Can Be Expected Now for Colon Cancer Due to Advances in Pharmacotherapy: Oncologist
July 5, 2017
- Long-Term Safety of PCSK9 Inhibitors Remains to Be Determined: New Atherosclerosis Prevention Guidelines
July 4, 2017
- Japanese Society of Hypertension to Verify Results of SPRINT Study
June 14, 2017
- AbbVie’s Novel Hep C Treatment Achieves 100% SVR in Genotype 1 Hepatitis C Patients with Compensated Cirrhosis
June 13, 2017
- DPP-4 Inhibitor Prevents Deterioration in Cardiac Diastolic Function in Diabetes Patients: Research Sub-Analysis
May 26, 2017
- Will Formularies Spread in Japan? Some Don’t Think So, but MOF Push Might Give Impetus
May 23, 2017
- “Authorized Biosimilars” Could Be Priced at 50% of Originators: Prof.
May 23, 2017
- JDS, JGS Publish 1st Guideline for Treatment of Diabetes in the Elderly
May 22, 2017
- PI/II Study Suggests Efficacy of Eisai’s Anti-Fractalkine Antibody for RA
April 25, 2017
- Gastric Cancer Guidelines Likely to Recommend Opdivo in 3rd Line Settings
April 24, 2017
- Hepatology Society to Release Updated Hep C Guidelines Soon, Reflecting Ximency Use
March 3, 2017
- NCC to Begin IIT for Pediatric ALL with Velcade Plus 5 Drugs
February 23, 2017
ページ
Pharma companies have seen Japan’s new “zero” premium coefficient rule extensively applied to medicines with low cost disclosure ratios since its introduction under the drug pricing reform this April. Of new drugs listed in the past two months, all six…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…